Biodesix (BDSX) said in a regulatory filing Friday that some stockholders are selling up to 62.2 million of their shares.
The selling stockholders include entities related to Biodesix's board directors: Westwood Management's chief executive officer Lawrence Kennedy Jr., Crabtree Partners' co-founders Jack Schuler and John Patience, as well as Birchview Capital's managing partner Matthew Strobeck, the filing showed.
Biodesix said it will not receive any proceeds from the sale.
Separately, Biodesix filed a registration statement to sell up to $250 million in securities from time to time.
The filing includes the sale of the company's common stock, preferred stock, warrants and units, as well as rights to purchase these securities.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.